newsfilter
← Latest News
PR Newswire·

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...